DRW Securities’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$15M Buy
12,500
+12,100
+3,025% +$12.4M 0.36% 45
2026
Q1
$368K Sell
400
-800
-67% -$811K 0.01% 779
2025
Q4
$1.29M Sell
1,200
-1,900
-61% -$1.82M 0.03% 255
2025
Q3
$2.37M Sell
3,100
-400
-11% -$298K 0.04% 219
2025
Q2
$2.73M Buy
+3,500
New +$2.72M 0.06% 167
2025
Q1
Sell
-700
Closed -$540K 704
2024
Q4
$540K Sell
700
-1,000
-59% -$828K 0.02% 319
2024
Q3
$1.51M Buy
1,700
+800
+89% +$719K 0.04% 219
2024
Q2
$821K Buy
900
+400
+80% +$320K 0.03% 272
2024
Q1
$389K Buy
+500
New +$356K 0.01% 247

Other funds holding LLY

DRW Securities's LLY Position: Q2 2026 in Review

DRW Securities sold out of Eli Lilly (LLY) in Q2 2026, closing a stake of 459 shares — an estimated $469K sold.

DRW Securities first reported a position in LLY in Q4 2017 and held it in 20 quarters. The position peaked at $9.1M in Q1 2025. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • DRW Securities reported no remaining Eli Lilly position as of Q2 2026 after selling out during the quarter.
  • DRW Securities sold 459 Eli Lilly shares in Q2 2026, an estimated $469K.
  • DRW Securities first reported a position in Eli Lilly in Q4 2017 and held it in 20 quarters.
  • DRW Securities's Eli Lilly position peaked at $9.1M in Q1 2025.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on DRW Securities's 13F filing for Q2 2026, filed 14 Aug 2026.